Rocket Lab Is Mispriced - Buy the Re-rate Ahead of Iridium and Contract Tailwinds

Hook & Thesis

Rocket Lab (RKLB) is trading at $63.90 right now, yet the market seems to have priced only the headline execution risk around Neutron and ignored two substantive balance-sheet and revenue levers: a near-term, margin-accretive acquisition (Iridium) and a widening pipeline of government communications work. At the current valuation, investors are implicitly assigning an enormous premium to future launch volume while undervaluing immediate, high-margin revenue that materially improves profitability.

We think that is wrong. This is a long trade: buy RKLB at $64.00 with a stop at $55.00 and a target at $95.00 on a long-term horizon (180 trading days). The trade rests on a) the Iridium acquisition closing and materially improving the company’s revenue and margins, and b) continued wins in defense-commercial optical communications that validate the Space Systems franchise.

What the Company Does and Why the Market Should Care

Rocket Lab operates two businesses: Launch Services (dedicated and rideshare missions) and Space Systems (spacecraft engineering, manufacturing, components, and on-orbit operations). The business mix has shifted meaningfully: today the company generates roughly 70%+ of revenue from space systems, moving it away from a pure-launch commoditized story and toward recurring, higher-margin services.

The near-term fundamental driver the market should care about is the Iridium acquisition, which would add $884 million of annual revenue with roughly 72% gross margins. That kind of revenue and margin profile is transformational: it takes a company that is currently loss-making on the P&L and moves it toward profitability and free cash flow generation on a consolidated basis.

Supporting Data & Recent Trends

Key numbers to anchor the thesis:

• Current price: $63.90; 52-week range: low $37.57 - high $150.9999.
• Market cap: approximately $38.24 billion; enterprise value: $40.02 billion.
• EPS (trailing): -$0.26 per share; free cash flow: -$371,139,000.
• Price-to-sales: 54.76x; EV-to-sales: 52.03x - both show the market is pricing substantial future revenue.
• Short interest: roughly 44.4 million shares (settlement 08/14/2026), days to cover ~2.18; recent short volume spikes indicate active short positioning but not an extreme squeeze metric.

Operationally, management continues to win program work. On 09/07/2026 Rocket Lab was selected for the U.S. Space Force Space Data Network Consortium and booked two delivery orders totaling $12 million to develop secure optical communications for military satellite operations. Those orders are small on their own but serve as validation of Photon interoperability and can scale into follow-on program work with multi-year revenue profiles and strong gross margins.

Separately, the company has a record backlog of launch missions, and second-quarter commentary pointed to robust year-over-year growth (one report cited Q2 sales growth near 62% YoY). Analysts are modeling a ~43% revenue CAGR through 2028 in some estimates - the market is willing to price that growth but is not fully crediting the immediate margin lift from Iridium.

Valuation Framing

At an enterprise value of ~$40.0 billion and current revenue expectations that exclude Iridium, RKLB is priced for a very high multiple of future launches and an aggressive growth trajectory. Price-to-sales of 54.8x is extreme against typical aerospace and defense comparables, which trade at single-digit to low double-digit revenue multiples when stable.

But valuation can change materially if you add $884M of revenue at 72% gross margins via Iridium. Rough math: a bolt-on that sizeable materially increases revenue base and EBITDA potential, compressing the headline revenue multiple and making near-term profitability credible. Put differently, a deal that converts a large portion of top-line into high-margin cash flow justifies a sizable re-rating even if Neutron timelines slip.

Catalysts (what will move the stock)

• Iridium merger progress and closing (expected mid-2027). Confirmation and incremental details on synergies and timeline would be the single largest re-rate catalyst.
• Delivery and demonstration milestones on Department of Defense optical communications work (operations expected with Photon in 2027). Successful demos can trigger follow-on awards.
• Quarterly results that show revenues and margins moving closer to breakeven; any guidance raising on adjacent services or recurring revenue would be positive.
• Commercial launch cadence stabilization and margin improvement in launch services, removing headline Neutron execution fears.

Trade Plan (actionable)

Entry: $64.00

Stop Loss: $55.00

Target: $95.00

Horizon: long term (180 trading days) - roughly nine months. This horizon aligns with the expected mid-2027 close of the Iridium transaction and allows time for the market to price in both the acquisition and follow-on contract wins. If the Iridium deal closes on schedule and initial integration metrics are disclosed, the re-rate should accelerate within this timeframe.

Risk management: the stop at $55.00 caps downside near ~14% from entry while leaving room for day-to-day volatility. Scale into the position if you can - an initial starter position at $64.00 with add-on allocations on constructive news is sensible here.

Risks & Counterarguments

Rocket Lab is not without material risks. A balanced view requires acknowledging at least four ways this trade can go wrong:

• Execution risk on Neutron: Further Neutron delays could keep the headlines negative and pressure sentiment even if financial impact is modest. Market perception matters and repeated slips can push multiples lower.
• M&A risk: The Iridium merger is transformational but contingent on closing and on the assumed margins proving accurate. Regulatory, financing, or integration issues could weaken expected accretion.
• Cash burn and FCF: Free cash flow is negative (about -$371M), and continued capital intensity or launch setbacks could require more equity or dilutive financing, which would punish the stock.
• Valuation risk: The company already trades at lofty revenue multiples. If growth disappoints or macro risk appetite falls, even good fundamentals may not prevent multiple compression.
• Counterargument: The market is correctly skeptical - Rocket Lab’s valuation embeds significant future performance. If the Iridium deal fails or generates lower-than-expected synergies, and Neutron under-delivers operationally, the current price could be the top of a multi-quarter downtrend.

Why I Still Prefer the Long Side

The counterarguments are valid, but they are second-order to the immediate financial transformation Iridium delivers. $884M of revenue at ~72% gross margin is not easy to dismiss: it meaningfully changes profitability dynamics. Meanwhile, the company is already winning high-margin government work (Space Data Network orders and Photon demos) that can scale. Short interest and recent insider exercises - including a pre-planned CFO sale at an exercise price well below today’s price - show both alignment and liquidity events that do not meaningfully de-risk the story but keep insiders invested.

What Would Change My Mind

I would step away from this trade if any of the following occurs:

• Iridium transaction faces clear regulatory rejection or material adverse findings that reduce expected revenue or margins.
• Free cash flow trends materially worsen and management signals a likely dilutive capital raise to fund operations.
• Consecutive quarterly revenue misses that point to persistent demand weakness in the Space Systems business.
• Short-term technical breakdown below $55.00 on accelerating volume that indicates a momentum washout beyond the controlled stop.

Conclusion

Rocket Lab is a high-conviction trade where upside is tied more to strategic repositioning (Iridium) and contract wins than to the single Neutron timeline. At $64.00 entry with a $55.00 stop and a $95.00 180-trading-day target, the risk/reward is compelling for investors willing to accept aerospace execution risk in exchange for an outsized re-rate if the acquisition and defense wins materialize. Keep position sizing appropriate to account for headline volatility, and use the stop to protect capital if sentiment turns against the story.

Key near-dates to watch: 09/07/2026 (Space Force SDN order disclosure), Q4 2026 (Neutron pad delivery window), and mid-2027 (expected Iridium closing).